These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27189916)

  • 1. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.
    Melmed GY; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Bressler B; Cheifetz AS; Devlin SM; Raffals LE; Vande Casteele N; Mould DR; Colombel JF; Dubinsky M; Sandborn WJ; Siegel CA
    Clin Gastroenterol Hepatol; 2016 Sep; 14(9):1302-9. PubMed ID: 27189916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.
    Melmed GY; Spiegel BM; Bressler B; Cheifetz AS; Devlin SM; Harrell LE; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Siegel CA
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):655-9. PubMed ID: 20451665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing anti-TNF treatments in inflammatory bowel disease.
    Ben-Horin S; Kopylov U; Chowers Y
    Autoimmun Rev; 2014 Jan; 13(1):24-30. PubMed ID: 23792214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology.
    Weizman AV; Nguyen GC; Seow CH; Targownik L; Murthy SK; Boland K; Afzal NM; Khanna R; Jones J; Afif W; Halder S; Reinglas J; Fowler S; Huang V; Kaplan GG; Melmed GY
    Inflamm Bowel Dis; 2019 Jan; 25(2):328-335. PubMed ID: 30346529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
    Samaan MA; Arkir Z; Ahmad T; Irving PM
    Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
    Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
    Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
    Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
    Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?
    Miheller P; Kiss LS; Lorinczy K; Lakatos PL
    Expert Opin Biol Ther; 2012 Feb; 12(2):179-92. PubMed ID: 22149260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies.
    Steenholdt C
    Dan Med J; 2016 Aug; 63(8):. PubMed ID: 27477799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases.
    Yarur AJ; Rubin DT
    Inflamm Bowel Dis; 2015 Jul; 21(7):1709-18. PubMed ID: 25901974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
    Strik AS; Berends SE; Löwenberg M
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):885-891. PubMed ID: 31305158
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
    Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease.
    Chaparro M; Guerra I; Muñoz-Linares P; Gisbert JP
    Aliment Pharmacol Ther; 2012 May; 35(9):971-86. PubMed ID: 22443153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.
    Vande Casteele N; Gils A
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S39-50. PubMed ID: 25707962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.
    Strik AS; Bots SJ; D'Haens G; Löwenberg M
    Expert Rev Clin Pharmacol; 2016; 9(3):429-39. PubMed ID: 26681400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.